SOFIE (PRIVATE.SOFIE)

Overall impact
D (28)

Commentary

SOFIE is a below-average overall performer. With a 'D' rating of 28.2 for overall impact (bottom 25% of all companies), SOFIE ranks 651st out of 652 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 647 others, and ahead of Opko Health. On top material causes for SOFIE's industry (Biotechnology), SOFIE performs well in Technology Innovation (94.9 score) and Technology Innovation (94.9) and performs poorly in Sustainable Use of Natural Resources (27.2 score), Decent, Safe Work Opportunities (0.0), Improved Mental Health (0.0) and 21 other causes where it received a 'D' or 'F' score.
Impact
Cause PRIVATE.SOFIE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2008
Employees
305
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Virginia, United States
Share classes
PRIVATE.SOFIE
Description
Developer of molecular imaging probes and devices designed to offer radiopharmaceutical products for Vivo research purposes. The company's devices help physicians to search throughout the body for tumors that will respond to drugs that target dCK, enabling caregivers to get access to theranostics and innovative technologies for personalized healthcare and for more patient-specific treatment selection.
Material causes
Ethos considers the following causes material for SOFIE, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.